Form 4: Akari Therapeutics Director Gaslightwala Receives Stock Options

Director Abizer Gaslightwala receives stock options in Akari Therapeutics Plc, including performance-based options tied to financing or licensing milestones.

Summary

• Abizer Gaslightwala, a director of Akari Therapeutics Plc, reported changes in beneficial ownership on March 24, 2025.
• The report details the grant of stock options under the company's 2023 Equity Incentive Plan.
• Gaslightwala was granted 1,100,000 stock options that vest over four years from the grant date of March 20, 2025.
• Additionally, Gaslightwala received 600,000 performance-based stock options that vest upon achieving specific milestones by December 31, 2025.
• These milestones include either a qualified financing of at least $15,000,000 or an ADC-focused license transaction with a minimum upfront payment of $10,000,000.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares of Akari Therapeutics.

Sentiment

Score: 7

Explanation: The document indicates standard compensation practices and incentives, suggesting a neutral to slightly positive outlook as it aligns director interests with company goals.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The performance-based options incentivize the achievement of key financial and strategic milestones for the company.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The performance-based options will expire if the specified financing or licensing milestones are not met by December 31, 2025.
• The value of the stock options is dependent on the future performance of Akari Therapeutics' stock price.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of performance-based options is contingent on achieving specific financial and strategic milestones by the end of 2025.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. Performance-based options are often used to drive specific strategic goals, such as securing financing or licensing agreements.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded biotechnology companies.
• The vesting schedule of four years with monthly vesting after the first year is a typical arrangement.
• Performance-based options tied to financing or licensing milestones are also common in the biotech industry, reflecting the importance of these events for company growth and value creation.
• Comparable companies such as BioNTech, Moderna, and Regeneron also utilize stock options and performance-based incentives as part of their executive compensation packages.

Stakeholder Impact

• Shareholders: The stock options align the director's interests with increasing shareholder value.
• Employees: The achievement of performance milestones could lead to company growth and opportunities for employees.

Key Dates

Keywords

stock options, Akari Therapeutics, director, Gaslightwala, Equity Incentive Plan, performance-based options, financing, licensing, ADS